The global attention deficit hyperactivity disorder market size was valued at US$ 17.4 billion in 2020 and is anticipated to grow at a CAGR of 7.4% during forecast period 2022 to 2030.
The global attention deficit hyperactivity disorder market size was valued at US$ 17.4 billion in 2020 and is anticipated to grow at a CAGR of 7.4% during forecast period 2022 to 2030.
Growth Factors
Product launches across the globe, approval of new drugs, and increased research and development activities are likely to drive the market.
An increase in awareness about mental health among the general population and governments is expected to propel the ADHD market. The rising number of people suffering from a host of mental health disorders, including attention-deficit/hyperactivity disorder, has caught the attention of governments around the world, forcing them to take necessary steps to address this condition. In 2016, the U.S. Department of Health & Human Services awarded up to USD 54 million to the Substance Abuse and Mental Health Services Administration (SAMHSA) for the next four years to address the needs of individuals with serious mental illnesses.
Key Market Trends
Stimulant Drug Type Segment is Expected to Projected Significant Growth Over the Forecast Period.
The stimulant segment dominated the ADHD market and is expected to continue to do so throughout the forecast period. This is due to the high demand for these drugs, which stems from their efficacy in treating symptoms of attention deficit hyperactivity disorder, ongoing clinical trials, and government support for the use of stimulants in the treatment of mental health disorders. Stimulant drugs include Amphetamine, Methylphenidate, Lisdexamfetamine, and Dexmethylphenidate.
Amphetamines (e.g., Adderall) and methylphenidate (e.g., Ritalin and Concerta) are common stimulant medications prescribed to children, adolescents, and adults with attention deficit hyperactivity disorder (ADHD). The study titled "A cognitive neuroscience review of the etiology of ADHD," published by the Association of Child and Adolescent Mental Health in January 2022, describe that stimulant works quickly, and there is also a reduction in overall impulsivity and ADHD symptoms in two hours. It also reported that stimulants are the most effective treatment for ADHD patients to keep them calm and focused. Thus the effectiveness of the stimulant drug in the management of ADHD boosts the segment growth over the forecast period.
Furthermore, a rise in clinical studies to evaluate the effectiveness of the stimulant drug in ADHD treatment is anticipated to drive the segment over the forecast period. For instance, as per the ClinicalTrial.gov updates on July 2021, the study titled "A Pivotal Efficacy Trial to Evaluate HLD200 (methylphenidate) in Children With ADHD in a Classroom Setting" under the development phase III by Ironshore Pharmaceuticals and Development, Inc. Hence, the increase in the number of drug development will be expected to increase in the accessibility of ADHD therapeutics and thus anticipated to boost the segment growth.
Moreover, the approval and commercialization of new drugs by market players are also expected to play a crucial role in driving market growth over the coming years. For instance, in March 2021, Azstarys (KemPharma) received Food and Drug Administration approval for a central nervous system stimulant for the treatment of ADHD. It is one of the first drugs with the combination of dexmethylphenidate and serdexmethylphenidate. Such approvals are propelling the growth of the market segment.
Thus, the aforementioned factors are likely to drive the growth of the segment during the forecast period.
COVID-19 Impact
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, faced problems with regard to the transportation of drugs and vaccines from one place to another. Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency. According to the World Health Organization’s report, manifestation of coronavirus (COVID-19) has resulted in more than 622,389,418 confirmed cases infected individuals worldwide as of 18 October, 2022.
Furthermore, psychological behavior in attention deficit hyperactivity disorder (ADHD) patients has worsen due to COVID-19 pandemic. For instance, according to the study published in the child and adolescent health, in THE LANCET journal, on April 17, 2020, it was found that during COVID-19 pandemic, the patients suffering from attention deficit hyperactivity disorder (ADHD) have become more vulnerable due to the stress caused by the pandemic. Thus due to COVID-19 has negatively impacted the patients of ADHD.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37275
Drug Type Insights
The stimulant drug type segment dominated the attention deficit hyperactivity disorder market with a revenue share of 71.91% in 2022 owing to the approval of the extended version of stimulant drugs as the most effective treatment that works in 70% - 80% of the cases. Stimulants are the most prescribed medications to treat attention deficit hyperactivity disorder. Recently, in March 2021, the U.S. FDA approved AZSTARYS developed by Kem Pharma, Inc. for the treatment of patients with ADHD aged 6 and above. Corium, Inc. is responsible for the commercialization of AZSTARYS in the U.S.
The non-stimulant drug type segment is expected to witness significant growth during the forecast period. This growth can be attributed to the approval of novel non-stimulant drug therapies to treat patients with the condition. For instance, in April 2021, the U.S. FDA approved Qelbree developed by Supernus Pharmaceuticals, Inc. for the treatment of children and adolescent patients ages 6 to 17 years. It is the first non-controlled non-stimulant product to be included in the ADHD treatment portfolio. This approval may attract a new target population and broaden the source of revenue.
Demographics Segment Insights
The adults segment dominated the attention deficit hyperactivity disorder (ADHD) market with a revenue share of 58.80% in 2022. Adults above 18 years of age suffering from ADHD have difficulty functioning in an academic environment, social & occupational environment. Currently, Ritalin, Focalin, Concerta, Daytrana, Quillivant XR, Aptensio SR, Evekeo, Elvanse, and Vyvanse are available brands of stimulant and non-stimulant drugs in the market to treat adult patients with ADHD.
The children segment is expected to grow at a high growth rate during the forecast period due to the rising prevalence of the disease. According to the ADHD Australia Report 2021, it affects over 800,000 Australian population accounting for 281,200 children aged 0 to 19 years and 533,300 adults aged 20 years and above. Approximately 2 of 3 children suffering from ADHD had at least other conditions such as anxiety, depression, mental, and emotional or behavioral disorder. Thus, an increasing number of children cases with ADHD is anticipated to drive segment growth.
Distribution Channel Segment Insights
The retail pharmacy segment dominated the attention deficit hyperactivity disorder market with a revenue share of 73.76% in 2022 and is anticipated to witness the fastest growth over the forecast period. This dominance can be attributed to the fact that most ADHD patients are treated in outpatient settings. Additionally, increase in focus on patient care initiatives, such as Greenway Medical Technologies, to provide personal Electronic Health Records (EHRs) to customers to keep track of medication history and basic care. Other factors boosting market growth are increasing healthcare expenditure, growing awareness of the disorder, and a rising volume of prescriptions for ADHD drugs.
The hospital pharmacy segment is expected to witness significant growth over the forecast period. Hospital pharmacists as medication experts can assist patients with ADHD and their parents with appropriate medication selection. Thus, the availability of multiple treatment options and the launch of new therapeutic products for better and more effective treatment with minimum side effects contribute the market growth. Based on an article published in 2022, around 388,000 (2.4%) children ages 2 to 5 years and 2.4 million (9.6%) ages 6 to 11 years have been diagnosed with ADHD. Thus, the growing aging population with ADHD acts as a major driver for the market.
Regional Insights
North America dominated the attention deficit hyperactivity disorder market in terms of the revenue share of 74.53% in 2022, owing to the launch and rapid uptake of multiple ADHD drugs. Increasing awareness about current treatment therapies, favorable reimbursement policies, and improved patient affordability are expected to drive market growth. According to the Centre for ADHD Awareness Canada (CADDAC), more than 1.5 million people are affected with ADHD in Canada.
Asia Pacific is expected to witness a growth rate of 6.2% over the forecast period. The growth of the region is attributed to the presence of key players in the market and strategic initiatives undertaken by them to develop and commercialize new products to treat patients. For instance, in February 2022, Siemens Healthcare GmbH and HMI Group entered into a partnership to support the development of a center of excellence to improve diagnosis, treatment, and care in Southeast Asia. This partnership boosts the research and development of novel ADHD drugs in Asia Pacific region.
Related Reports
- Post-traumatic Stress Disorder Treatment Market - https://www.visionresearchreports.com/post-traumatic-stress-disorder-treatment-market/39888
- Autism Spectrum Disorder Treatment Market - https://www.visionresearchreports.com/autism-spectrum-disorder-treatment-market/39768
- Bipolar Disorder Market - https://www.visionresearchreports.com/bipolar-disorder-market/37829
Key Players
li Lily & Company; Pfizer; Johnson & Johnson Services, LLC; Lupin; Shire; Mallinckrodt; Prude Pharma L.P.; and NEOS Therapeutics Inc.
Market Segmentation
- Drug Outlook
- Amphetamine
- Methylphenidate
- Lisdexamfetamine
- Dexmethylphenidate
- Atomoxetine
- Guanfacine
- Clonidine
- Bupropion
- Drug Type Outlook
- Stimulant
- Non-stimulant
- Demographic Outlook
- Adult (Aged 18 and above)
- Children
- Distribution Channel Outlook
- Retail Pharmacy
- Hospital Pharmacy
- Regional Outlook
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37275
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/